La cadena de opciones muestra datos clave de las opciones de acciones de Clearside Biomedical a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Clearside Biomedical..

Clearside Biomedical (NASDAQ:CLSD) Bolsa, Cadena de Opciones

CLEARSIDE BIOMEDICAL INC

Clearside Biomedical

Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical Inc

Earnings

Press Releases

Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

News

Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Health Care

Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference

Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update

Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum

Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting

General

Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline

Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada

CLSD

AN2 Therapeutics

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Aytu BioPharma

CalciMedica

Cingulate

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Grace Therapeutics

Hyperion DeFi

IGC Pharma

Iterum Therapeutics

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Lexaria Bioscience

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

Pulmatrix

PolyPid

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals

SCYNEXIS

SenesTech

Telomir Pharmaceuticals, Inc. - Common Stock

Comments

Clearside Biomedical

Clearside Biomedical (CLSD) Opciones

Clearside Biomedical (NASDAQ:CLSD) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL